Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06656494 · ClinicalTrials.gov registry record · Phase 1
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
A Phase 1 study of Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS), sponsored by Beijing InnoCare Pharma Tech Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 266
- Enrollment target
- 15
- Study locations
NCT06656494: Recruiting Phase 1 study of Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS), sponsored by Beijing InnoCare Pharma Tech Co..
NCT06656494 is a Phase 1 study of Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS) that is actively recruiting participants, run by Beijing InnoCare Pharma Tech Co.. The registered enrollment target is 266 participants, above the 133-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (100% higher). The trial reports 15 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06656494, a Phase 1 study of Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS), is actively recruiting participants, sponsored by Beijing InnoCare Pharma Tech Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 266 participants
- Enrollment target
- 15
- Study locations
Study Summary
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG ICP-248
Study Locations (15)
Guangdong
- Guangdong Provincial People's Hospital - Guangzhou
- Nanfang Hospital Southern Medical University - Guangzhou
New York
- NYU Langone Health - New York
Anhui
- Anhui Provincial Hospita - Hefei
Beijing Municipality
- Peking University People's Hospital - Beijing
Chongqing Municipality
- The First Affiliated Hospital of Chongqing Medical University - Chongqing
Henan
- Henan Cancer Hospital - Zhengzhou
Hubei
- Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan
Jiangsu
- The First Affiliated Hospital of Soochow University - Suzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT06656494 shows while recruiting
NCT06656494 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (100% higher).
The record links to 2 conditions, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT06656494 lists 15 locations in 14 states (Guangdong, New York, Anhui).
Frequently Asked Questions
What is clinical trial NCT06656494 about?
NCT06656494 is a clinical study titled "ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies". Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
What is the current status of trial NCT06656494?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 266 participants. The study started on 2024-12-18. Estimated completion is 2028-01.
What conditions does trial NCT06656494 study?
This clinical trial studies the following conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS).
What interventions are being tested in trial NCT06656494?
The interventions under investigation include: Azacitidine (DRUG), ICP-248 (DRUG).
Who is sponsoring clinical trial NCT06656494?
This trial is sponsored by Beijing InnoCare Pharma Tech Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06656494 being conducted?
This trial has 15 study locations across New York, Anhui, Beijing Municipality, Chongqing Municipality, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06656494's enrollment target sits among peer trials
266 5th of 38 higher than 34 of 38 other Acute Myelogenous Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myelogenous Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
ACTIVE NOT RECRUITING · Phase 1
-
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
COMPLETED · Phase 1
-
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
COMPLETED · Phase 1
-
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05098652 · 266 participants · NA
Coaching Dementia Caregivers to Master Care-Resistant Behavior
- NCT06088277 · 266 participants · NA
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
- NCT06261814 · 266 participants · Phase 2
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
- NCT06312124 · 266 participants · NA
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI